Fig. 3
From: Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
A Heatmap of fold changes between treated groups [glimepiride (G) vs. liraglutide (L)]. B Selected examples of lipids, i.e., phosphatidylcholine [PC(36:4)], phosphatidylethanolamines [PE(18:1/8:2)], lysophosphatidylcoline [LPC(18:2)] and triacylglycerol [TG(18:0/18:1/20:4)], showing significant difference between treated groups [glimepiride (G) vs. liraglutide (L)], with adjusted p values marked to the boxplots